RMgmDB - Rodent Malaria genetically modified Parasites


Malaria parasiteP. berghei
MutatedGene model (rodent): PBANKA_0208800; Gene model (P.falciparum): PF3D7_0104300; Gene product: ubiquitin carboxyl-terminal hydrolase 1, putative (UBP1)
Details mutation: UBP1 mutated - V2721F
Phenotype Asexual bloodstage;
Last modified: 11 November 2020, 17:12
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene mutation
Reference (PubMed-PMID number) Reference 1 (PMID number) : 32340987
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 820cl1m1cl1 (RMgm-164)
Other information parent lineP. berghei ANKA 820cl1m1cl1 (RMgm-164) is a reference ANKA mutant line which expresses GFP under control of a male and RFP under control of a female gametocyte specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 19438517).
The mutant parasite was generated by
Name PI/ResearcherSimwela NV, Waters AP
Name Group/DepartmentInstitute of Infection, Immunity & Inflammation, Wellcome Centre for Integrative Parasitology
Name InstituteUniversity of Glasgow
Name of the mutant parasite
RMgm numberRMgm-4828
Principal nameG1808(V2721F)
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Asexual blood stageBlood stages show different susceptibility to drugs (V2721F UBP mutation results in reduced artemisinin susceptibility)
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

The mutant expresses a mutated UBP1 (V2721F)

Protein (function)

Mutations in a ubiquitin hydrolase, UBP (HAUSP or USP7 close homologue), were previously identified to modulate susceptibility to ART and chloroquine (CQ) in the rodent infectious malaria parasite, Plasmodium chabaudi

Evidence is presented that V2721F UBP mutation results in reduced artemisinin susceptibility, while the V2752F mutation results in resistance to chloroquine and moderately impacts tolerance to artemisinins

Additional information

Other mutants

  Mutated: Mutant parasite with a mutated gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0208800
Gene Model P. falciparum ortholog PF3D7_0104300
Gene productubiquitin carboxyl-terminal hydrolase 1, putative
Gene product: Alternative nameUBP1
Details of the genetic modification
Short description of the mutationUBP1 mutated - V2721F
Inducable system usedNo
Short description of the conditional mutagenesisNot available
Additional remarks inducable system
Type of plasmid/constructCRISPR/Cas9 construct: integration through double strand break repair
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasiteunknown
Promoter of the selectable markerunknown
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationSee the paper for more details for the CRISPR/cas9 constructs and selection procedures
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6